Medication info
Pregablin Capsule 150 mg (Pregabalin)

Pregablin Capsule 150 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›150mg / 1 capsule
Manufacturer / importer
Genupa Co., Ltd.
Appearance
White hard capsule containing white powder
Packaging
30 capsules/bottle, 60 capsules/bottle
Approval status
Active

MFDS item code 201702386 · Approved 2017.05.16 · Insurance code 698003530

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures in epilepsy
Who takes it
Adults · Children
Adult dose
This medicine is administered orally, with or without food, with the total daily dose of pregabalin divided into 2 doses. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to up to 300 mg per day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is excreted primarily by the kidneys in unchanged form. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. Creatinine clearance (CLcr), (mL/min) | Initial dose (mg/day) | Maximum dose (mg/day) | Administration ≥60 | 150 | 600 | BID or TID ≥30 -<60 | 75 | 300 | BID or TID ≥15 -<30 | 25-50 | 150 | QD or BID <15 | 25 | 75 | QD Supplemental dose after hemodialysis | 25 | 100 | Single dose b This medicine is effectively removed from plasma by hemodialysis. (Approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined according to renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. TID = Total daily dose administered in 3 divided doses BID = Total daily dose administered in 2 divided doses QD = Administered once daily a: The total daily dose (mg/day) should be divided as specified under Administration. b: Supplemental dose refers to an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
Children under 12 years of age: Use is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 ~17 years: Use is not recommended because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
Genupa Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures in epilepsy

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to treat peripheral and central neuropathic pain in adults and is used as an adjunctive treatment for partial seizures in patients with epilepsy. It also helps alleviate the symptoms of fibromyalgia. Due to its effectiveness in various neurological conditions, it is used to improve the pain and symptoms of patients.

How to take

Adult dose

This medicine is administered orally, with or without food, with the total daily dose of pregabalin divided into 2 doses. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to up to 300 mg per day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is excreted primarily by the kidneys in unchanged form. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. Creatinine clearance (CLcr), (mL/min) | Initial dose (mg/day) | Maximum dose (mg/day) | Administration ≥60 | 150 | 600 | BID or TID ≥30 -<60 | 75 | 300 | BID or TID ≥15 -<30 | 25-50 | 150 | QD or BID <15 | 25 | 75 | QD Supplemental dose after hemodialysis | 25 | 100 | Single dose b This medicine is effectively removed from plasma by hemodialysis. (Approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined according to renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. TID = Total daily dose administered in 3 divided doses BID = Total daily dose administered in 2 divided doses QD = Administered once daily a: The total daily dose (mg/day) should be divided as specified under Administration. b: Supplemental dose refers to an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

Children under 12 years of age: Use is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 ~17 years: Use is not recommended because there are insufficient data on safety and efficacy.

Precautions

This drug may increase the risk of suicidal thoughts or behavior; if during treatment there are signs of depression or mood changes, consult your doctor immediately. Patients with hypersensitivity to this medication or specific genetic issues like lactose intolerance should not take it. Diabetic patients should be cautious as weight gain may require adjustments to blood sugar-controlling medications. If allergic reactions such as angioedema occur, stop taking the medication immediately and seek medical attention. Elderly patients should be particularly careful when starting the medication due to the risk of dizziness or drowsiness, which may lead to falls. Vision blurriness or changes may occur, so consult your doctor if these symptoms happen. Discontinuing this medication abruptly may lead to withdrawal symptoms such as insomnia, headaches, and anxiety, so it should be gradually reduced under a doctor’s supervision. There is a risk of drug abuse; thus, patients with a history of substance abuse should be particularly cautious and report any unusual behaviors immediately. Patients with impaired kidney function may need a dose adjustment, so consult your doctor. Caution is required for patients with heart disease while taking this medication. Taking this medication in combination with opioid analgesics may increase the risk of central nervous system depression, so be cautious during concurrent use. Patients with weak respiratory function or elderly individuals may be at risk of severe respiratory depression and may require dosage adjustments. Pregnant women should avoid this medication, especially in early pregnancy, due to potential congenital malformations for the fetus, and women of childbearing age should use effective contraception. Breastfeeding women should consider the possibility of this medication passing into breast milk and potentially affecting the baby, and should make a careful decision regarding breastfeeding. It is advisable to avoid activities requiring attention, such as driving or operating machinery, during the initial period of taking this medication. Severe skin reactions may occur infrequently, so if skin rashes or other unusual symptoms develop, stop taking the medication and consult your doctor immediately. Overdose may cause drowsiness, confusion, depression, and may require treatments such as hemodialysis.

Side effects

Suicidal thoughts, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, swelling around the mouth and upper respiratory tract, dizziness, drowsiness, loss of consciousness, confusion, mental disorders, blurred vision, changes in vision, insomnia, headache, nausea, anxiety, diarrhea, influenza-like illness, restlessness, suicidal ideation, pain, seizures, sweating, misuse, abuse, dependence, congestive heart failure, severe respiratory depression, rhinitis, neutropenia, increased appetite, decreased appetite, hypoglycemia, confusion, disorientation, irritability, euphoria, decreased libido, depersonalization, dysesthesia, restlessness, agitation, mood swings, emotional decline, emotional elevation, hallucinations, abnormal dreams, increased libido, panic attacks, impulsivity, flat affect, ataxia, motor coordination disorders, balance disorders, amnesia, attention deficits, memory impairment, tremors, dysarthria, sensory abnormalities, sensory loss, sedation, somnolence, cognitive impairment, nystagmus, speech disorder, fasciculations, reflex reduction, movement abnormalities, psychomotor agitation, positional dizziness, hyperesthesia, burning sensation, action tremors, syncope, confusion, motor slowing, olfactory abnormalities, loss of taste, writing difficulties, diplopia, vertigo, auditory hyperesthesia, first-degree atrioventricular block, tachycardia, bradycardia, supraventricular tachycardia, ventricular arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, difficulty breathing, nasal bleeding, cough, nasal congestion, rhinitis, snoring, throat tension, nasal dryness, respiratory depression, vomiting, abdominal distension, constipation, dry mouth, bloating, excessive salivation, gastroesophageal reflux, oral sensory impairment, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweat, muscle cramps, arthralgia, back pain, limb pain, cervical cramps, joint swelling, myalgia, muscle spasms, neck pain, muscle rigidity, rhabdomyolysis, urinary disorders, incontinence, decreased urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, breast pain, breast discharge, breast enlargement, peripheral edema, edema, gait abnormalities, falls, feelings of intoxication, sensory abnormalities, fatigue, tightness in the chest, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased creatine phosphokinase in blood, increased aspartate aminotransferase, increased blood sugar, decreased platelet count, decreased potassium in blood, weight loss, increased creatinine in blood, decreased white blood cell count, hypersensitivity, allergic reactions, headache, keratitis, pulmonary edema, nausea, diarrhea, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, malaise, delirium, paralysis (facial paralysis), affective disorders, drowsiness, confused state, excitement, restlessness, worsened seizures, shock, anaphylaxis-like symptoms, mucocutaneous syndrome, erythema multiforme

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture and is best kept at room temperature, between 15°C and 30°C. This storage preserves the medication's efficacy over time and prevents degradation.

Appearance and packaging

Appearance

White hard capsule containing white powder

Package unit

30 capsules/bottle, 60 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.